JP6166858B2 - 細胞内損傷の治療のための組成物および方法 - Google Patents

細胞内損傷の治療のための組成物および方法 Download PDF

Info

Publication number
JP6166858B2
JP6166858B2 JP2013556899A JP2013556899A JP6166858B2 JP 6166858 B2 JP6166858 B2 JP 6166858B2 JP 2013556899 A JP2013556899 A JP 2013556899A JP 2013556899 A JP2013556899 A JP 2013556899A JP 6166858 B2 JP6166858 B2 JP 6166858B2
Authority
JP
Japan
Prior art keywords
pif
seq
peptide
months
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013556899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508164A (ja
JP2014508164A5 (OSRAM
Inventor
アール． バーネア、エイタン
アール． バーネア、エイタン
Original Assignee
バイオインセプト、エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオインセプト、エルエルシー filed Critical バイオインセプト、エルエルシー
Publication of JP2014508164A publication Critical patent/JP2014508164A/ja
Publication of JP2014508164A5 publication Critical patent/JP2014508164A5/ja
Application granted granted Critical
Publication of JP6166858B2 publication Critical patent/JP6166858B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2013556899A 2011-03-02 2012-03-02 細胞内損傷の治療のための組成物および方法 Expired - Fee Related JP6166858B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161448446P 2011-03-02 2011-03-02
US61/448,446 2011-03-02
PCT/US2012/027480 WO2012119072A2 (en) 2011-03-02 2012-03-02 Compositions and methods for treatment of intracellular damage

Publications (3)

Publication Number Publication Date
JP2014508164A JP2014508164A (ja) 2014-04-03
JP2014508164A5 JP2014508164A5 (OSRAM) 2015-04-23
JP6166858B2 true JP6166858B2 (ja) 2017-07-19

Family

ID=46758515

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013556899A Expired - Fee Related JP6166858B2 (ja) 2011-03-02 2012-03-02 細胞内損傷の治療のための組成物および方法

Country Status (5)

Country Link
US (3) US9737585B2 (OSRAM)
EP (1) EP2680872B1 (OSRAM)
JP (1) JP6166858B2 (OSRAM)
IL (1) IL228205B (OSRAM)
WO (1) WO2012119072A2 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
EP2680872B1 (en) 2011-03-02 2018-08-15 BioIncept LLC Use of pif peptides for treating infections, atherosclerosis and peritonitis
EP3060924B1 (en) * 2013-10-22 2022-06-01 Bioincept LLC Pif-transfected cells and methods of use
US20170319645A1 (en) * 2014-09-16 2017-11-09 Bioincept, Llc Compositions and methods for treating acute radiation syndrome
EP3215847A4 (en) * 2014-11-03 2018-02-14 Bioincept LLC Pif binding as a marker for immune dysregulation
TWI701249B (zh) 2015-03-13 2020-08-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用
TWI698438B (zh) 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用
US11096987B2 (en) 2015-08-28 2021-08-24 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
EP3341006A4 (en) 2015-08-28 2019-03-13 BioIncept LLC COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
CA3071012A1 (en) * 2017-07-17 2019-01-24 Bioincept, Llc Peptides and methods of transplantation and restorative organ function

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5658792A (en) 1990-11-14 1997-08-19 The United States Of America As Represented By The Department Of Health And Human Services Antiproliferative protein
IL96499A0 (en) 1990-11-28 1991-08-16 Eytan Barnea Anticancer protein-like extract
US5648340A (en) 1991-10-31 1997-07-15 Barnea; Eytan R. Gestational agents for controlling cell proliferation
US5393534A (en) 1992-04-09 1995-02-28 Board Of Regents, The University Of Texas System Liver-derived tumor cell growth inhibitor
US5279941A (en) 1992-06-12 1994-01-18 Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
WO1994006464A1 (en) 1992-09-17 1994-03-31 New York University Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites
US5891623A (en) 1992-11-09 1999-04-06 Consorzio Per Le Biotecnologie Diagnosis and treatment of AIDS onset
DE4400640A1 (de) 1994-01-12 1995-07-13 Eftag Entstaubung Foerdertech Verwendung von, Mittel mit und Verfahren zur Herstellung eines Arzneimittels mit Embryonalgewebe
US5646003A (en) 1994-03-23 1997-07-08 Barnea; Eytan R. Preimplantation factor
GB9406492D0 (en) 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
US6489441B1 (en) 1995-09-01 2002-12-03 The Salk Institute For Biological Studies Transcriptional co-repressor that interacts with nuclear hormone receptors
US6585979B1 (en) 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
SE9701912D0 (sv) 1997-05-22 1997-05-22 Interhealth Ab Pharmaceutical composition and use thereof
US6225097B1 (en) 1997-09-17 2001-05-01 Toyota Jidosha Kabushiki Kaisha Decaprenyl diphosphate synthetase gene
US6171591B1 (en) 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
KR19990075721A (ko) 1998-03-24 1999-10-15 허일섭 당뇨병 특이 변이종 내인성 레트로바이러스의 유전자 및이로부터 유추되는 아미노산 서열
WO2000001402A1 (en) 1998-07-02 2000-01-13 Envision Biomedical Consulting Antiproliferative and antiviral proteins and peptides
WO2001022920A2 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
AU7854400A (en) 1999-10-08 2001-04-23 Envision Biomedical Consulting Gestational agents which modulate cell proliferation
US20020004205A1 (en) 2000-03-30 2002-01-10 Consler Thomas G. Method of investigating functional molecular interactions and reagents for use therein
UA74575C2 (uk) 2000-05-01 2006-01-16 Sanders John Larry Аніонні полімери на основі вінілу і дикарбонової кислоти, способи їх одержання (варіанти), композиція на їх основі та способи посилення росту рослин за їх допомогою
US7198895B2 (en) 2000-11-14 2007-04-03 Mohanlal Ramon W In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals
IL156770A0 (en) 2001-01-04 2004-02-08 Vascular Biogenics Ltd Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
US20030105003A1 (en) * 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
JP4593106B2 (ja) 2001-07-02 2010-12-08 バイオインセプト、エルエルシー 着床前因子の新しいアッセイ方法および着床前因子ペプチド
US8222211B2 (en) 2001-07-02 2012-07-17 Bioincept, Llc Methods of administering PIF agonist peptides and uses thereof
US20060104963A1 (en) 2002-07-25 2006-05-18 The Scripps Research Institute Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells
US8017745B2 (en) 2002-12-06 2011-09-13 Epimmune Inc. Plasmodium falciparum antigens and methods of use
WO2005030791A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
US7709476B2 (en) * 2003-09-23 2010-05-04 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
WO2005040196A2 (en) 2003-10-22 2005-05-06 Bioincept, Llc Pif peptides biologic activities, site of action, and the antibody to detect pif
US7723289B2 (en) 2003-10-22 2010-05-25 Bioincept, Llc PIF tetrapeptides
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
WO2009120186A1 (en) * 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Methods and compositions for treating atherosclerosis and related conditions
EP2680872B1 (en) 2011-03-02 2018-08-15 BioIncept LLC Use of pif peptides for treating infections, atherosclerosis and peritonitis

Also Published As

Publication number Publication date
EP2680872B1 (en) 2018-08-15
US20210244789A1 (en) 2021-08-12
EP2680872A4 (en) 2014-11-05
IL228205B (en) 2020-02-27
WO2012119072A3 (en) 2013-01-17
EP2680872A2 (en) 2014-01-08
WO2012119072A2 (en) 2012-09-07
US20180021401A1 (en) 2018-01-25
US10953071B2 (en) 2021-03-23
US20140147414A1 (en) 2014-05-29
JP2014508164A (ja) 2014-04-03
US9737585B2 (en) 2017-08-22

Similar Documents

Publication Publication Date Title
JP6166858B2 (ja) 細胞内損傷の治療のための組成物および方法
GIROIR Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cascade
Shalaby et al. The involvement of human tumor necrosis factors-alpha and-beta in the mixed lymphocyte reaction.
DeLyria et al. Vaccination of mice against H pylori induces a strong Th-17 response and immunity that is neutrophil dependent
KR101554056B1 (ko) 자가면역 질환의 치료 및/또는 예방 및 조절 ｔ세포의 형성을 위한 수단
JP6054889B2 (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ−２の使用
JP5680661B2 (ja) Ｉｌ−２に由来する免疫調節ポリペプチド並びに癌及び慢性感染症の治療におけるその使用
JP3494647B2 (ja) Ｉｌ−４および／またはｉｌ−１０ならびにそれらに対する抗体の新規な用途
JP5493076B2 (ja) Ｃｄｃａ１ペプチド及びこれを含む薬剤
JP2009511637A (ja) Ｈｌａクラスｉｉ結合ｗｔ１ペプチド及びその組成物、並びにその作成方法
SA519410007B1 (ar) مركبات ببتيد وطرق لمعالجة السكر
JPH08500083A (ja) ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制
JPH06510672A (ja) サプレッサーおよび前駆細胞
US20190022181A1 (en) Mutant Peptides And Methods Of Treating Subjects Using The Same
JPH07502019A (ja) 内毒素または超抗原に誘導された毒性を治療するインターロイキン−１０類似体またはアンタゴニストの使用
JP2007500693A (ja) 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法
CA2557654A1 (en) Peptides of il1 beta and tnf alpha and method of treatment using same
KR102421307B1 (ko) 암 발생 및 성장 억제를 위한 신규 항암 백신 조성물 및 그를 이용한 백신화 방법
Pelidou et al. Intranasal Administration of Recombinant Mouse Interleukin‐12 Increases Inflammation and Demyelination in Chronic Experimental Autoimmune Neuritis in Lewis Rats
AU2017378378A1 (en) Methods of treating diseases associated with ILC2 cells
JPH11510806A (ja) 免疫抑制治療のためのインターロイキン１０およびシクロスポリンの併用
JP2023503630A (ja) 糖尿病患者を階層化する方法
CN112546228A (zh) 非igf1r结合型的物质在预防和/或治疗炎症性疾病中的应用
US20040116344A1 (en) Immunomodulatory properties of bip
JP2009533478A (ja) 黄色ブドウ球菌感染症の治療用薬剤の製造のための活性成分としてｔｒａｐタンパク質自体の使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170624

R150 Certificate of patent or registration of utility model

Ref document number: 6166858

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees